Special Issue "Advance Research in Neoepitopes, Cancer Vaccines and Immune Monitoring"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Tumor Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 May 2019).

Special Issue Editor

Dr. Pirouz Daftarian
E-Mail Website
Guest Editor
1. JSR Micro Life Sciences and MBL International, 1280 N Mathilda Ave. Sunnyvale, CA, 94089, USA
2. Department of Biochemistry and Molecular Biology, University of Miami Leonard M. Miller School of Medicine, Miami, United States
Interests: cancer vaccine; neoantigens; personalized medicine; adjuvants; nanocarriers; peptide-MHC; MHC Tetramers; nucleic acid based-vaccines

Special Issue Information

Dear Colleagues,

The cancer immunology stage has never been this equipped for cancer vaccines. Neoantigen discovery and validation has been advancing expeditiously. The first wave of neoantigen-based vaccine discoveries has been very exciting in a personalized nature, which seem to be further promising based on new reports on public neoantigens. To this end, the development of nucleic-based cancer vaccines encoding for the neoepitopes, and later their novel nanocarriers, with positive preclinical data, have gotten closer to being injected into humans. Moreover, peptide-MHC-based cancer vaccines or their biosimilars and those that are bi-specific, carrying other immunomodulatory moieties, are being designed and tested, adding to the excitement of modern cancer vaccines. More importantly, only a fraction of cancer patients benefits from immune checkpoint blockades (ICBs), those that have intrinsic tumor specific T cell responses. Cancer vaccines are perhaps the best practical approach to elicit anti-tumor responses in naïve hosts. This Special Issue will include original research, review articles, commentaries, and editorials discussing the design, use, and immunomonitoring of various types of cancer vaccines. Topics of interest for this Special Issue include, but are not limited to, the keywords listed below.

Dr. Pirouz Daftarian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer vaccine
  • neoantigens
  • neoepitope
  • personalized medicine
  • adjuvants
  • nanocarriers
  • peptide-MHC
  • MHC Tetramers
  • nucleic acid based-vaccines
  • immune monitoring of vaccines
  • nucleic acid-based vaccines
  • Dendritic based cancer vaccines
  • tumor specific antigens
  • public neoantigens

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma
Biomedicines 2019, 7(4), 91; https://doi.org/10.3390/biomedicines7040091 - 23 Nov 2019
Abstract
Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed [...] Read more.
Archaeosomes are liposomes composed of natural or synthetic archaeal lipids that when used as adjuvants induce strong long-lasting humoral and cell-mediated immune responses against entrapped antigens. However, traditional entrapped archaeosome formulations have only low entrapment efficiency, therefore we have developed a novel admixed formulation which offers many advantages, including reduced loss of antigen, consistency of batch-to-batch production as well as providing the option to formulate the vaccine immediately before use, which is beneficial for next generation cancer therapy platforms that include patient specific neo-antigens or for use with antigens that are less stable. Herein, we demonstrate that, when used in combination with anti-CTLA-4 and anti-PD-1 checkpoint therapy, this novel admixed archaeosome formulation, comprised of preformed sulfated lactosyl archaeol (SLA) archaeosomes admixed with OVA antigen (SLA–OVA (adm)), was as effective at inducing strong CD8+ T cell responses and protection from a B16-OVA melanoma tumor challenge as the traditionally formulated archaeosomes with encapsulated OVA protein. Furthermore, archaeosome vaccine formulations combined with anti-CTLA-4 and anti-PD-1 therapy, induced OVA-CD8+ T cells within the tumor and immunohistochemical analysis revealed the presence of CD8+ T cells associated with dying or dead tumor cells as well as within or around tumor blood vessels. Overall, archaeosomes constitute an attractive option for use with combinatorial checkpoint inhibitor cancer therapy platforms. Full article
Show Figures

Graphical abstract

Back to TopTop